Samir Undevia

Samir Undevia

UNVERIFIED PROFILE

Are you Samir Undevia?   Register this Author

Register author
Samir Undevia

Samir Undevia

Publications by authors named "Samir Undevia"

Are you Samir Undevia?   Register this Author

27Publications

595Reads

21Profile Views

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.

Cancer 2020 Jan 11;126(1):105-111. Epub 2019 Sep 11.

Pennsylvania Oncology Hematology Associates, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32515
Publisher Site
http://dx.doi.org/10.1002/cncr.32515DOI Listing
January 2020

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.

Invest New Drugs 2015 Aug 8;33(4):901-10. Epub 2015 May 8.

Department of Medicine, University of Chicago, MC2115, 5841 South Maryland Avenue, Chicago, IL, 60637, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0247-1DOI Listing
August 2015

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

J Clin Oncol 2014 Aug 23;32(22):2328-34. Epub 2014 Jun 23.

Federico Innocenti, Richard L. Schilsky, Jacqueline Ramírez, Linda Janisch, Samir Undevia, Larry K. House, Soma Das, Kehua Wu, Michelle Turcich, Theodore Karrison, Michael L. Maitland, Ravi Salgia, and Mark J. Ratain, University of Chicago, Chicago; and Robert Marsh, NorthShore University Health System, Evanston, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.2307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105486PMC
August 2014

A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.

Pharmacogenet Genomics 2014 Feb;24(2):129-32

aDepartment of Medicine, The University of Chicago, Chicago, Illinois bDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901533PMC
February 2014

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis.

Ann Surg Oncol 2012 May;19(5):1410-5

Division of Surgical Oncology, Department of Surgery, The University of Illinois at Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-012-2240-7DOI Listing
May 2012

A phase I study of continuous infusion cilengitide in patients with solid tumors.

Invest New Drugs 2012 Apr 14;30(2):604-10. Epub 2010 Sep 14.

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9537-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059335PMC
April 2012

R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.

Eur J Cancer 2009 Jul 21;45(11):1904-8. Epub 2009 May 21.

Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2009.04.032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758059PMC
July 2009

Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.

Cancer 2008 Jun;112(11):2432-9

Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23478DOI Listing
June 2008

A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.

Cancer Biol Ther 2007 Apr;6(4):490-3

University of Chicago Phase II Consortium, Section of Hematology/Oncology, Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.6.4.3831DOI Listing
April 2007

Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor.

J Neurooncol 2005 Sep;74(2):183-5

The Department of Neurology, The University of Chicago School of Medicine and Medical Center, 5841 S. Maryland Street, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-004-4596-4DOI Listing
September 2005

Pharmacokinetic variability of anticancer agents.

Nat Rev Cancer 2005 Jun;5(6):447-58

Cancer Research Center, The University of Chicago, 5841 South Maryland Avenue, MC 2115 Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc1629DOI Listing
June 2005

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Invest New Drugs 2004 Nov;22(4):449-58

Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/B:DRUG.0000036687.26604.8cDOI Listing
November 2004

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.

Clin Pharmacol Ther 2004 Nov;76(5):490-502

Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clpt.2004.07.016DOI Listing
November 2004

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.

Clin Cancer Res 2004 Jul;10(13):4406-11

Section of Hematology/Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-0083DOI Listing
July 2004